The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 08, 2016

Filed:

Feb. 22, 2007
Applicants:

Guy M. Miller, Monte Sereno, CA (US);

Sidney M. Hecht, Charlottesville, VA (US);

Orion D. Jankowski, Burlingame, CA (US);

Kieron E. Wesson, Menlo Park, CA (US);

Paul Mollard, Saratoga, CA (US);

Inventors:

Guy M. Miller, Monte Sereno, CA (US);

Sidney M. Hecht, Charlottesville, VA (US);

Orion D. Jankowski, Burlingame, CA (US);

Kieron E. Wesson, Menlo Park, CA (US);

Paul Mollard, Saratoga, CA (US);

Assignee:

Edison Pharmaceuticals, Inc., Mountain View, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/355 (2006.01); A61K 31/05 (2006.01); C07C 39/08 (2006.01); C07C 39/11 (2006.01); C07C 39/19 (2006.01); C07C 39/24 (2006.01); C07C 50/02 (2006.01); C07C 50/06 (2006.01); C07C 50/24 (2006.01); C07C 50/28 (2006.01); C07C 215/56 (2006.01); C07C 403/04 (2006.01); C07C 403/08 (2006.01); C07C 403/18 (2006.01);
U.S. Cl.
CPC ...
A61K 31/355 (2013.01); A61K 31/05 (2013.01); C07C 39/08 (2013.01); C07C 39/11 (2013.01); C07C 39/19 (2013.01); C07C 39/245 (2013.01); C07C 50/02 (2013.01); C07C 50/06 (2013.01); C07C 50/24 (2013.01); C07C 50/28 (2013.01); C07C 215/56 (2013.01); C07C 403/04 (2013.01); C07C 403/08 (2013.01); C07C 403/18 (2013.01); C07C 2101/16 (2013.01);
Abstract

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.


Find Patent Forward Citations

Loading…